Loading...
•
Jun 30, 2022
AcelRx Q2 2022 Earnings Report
Reported a successful quarter of growth for DSUVIA and cost reduction measures were implemented.
Key Takeaways
AcelRx Pharmaceuticals reported Q2 2022 financial results, highlighting $0.6 million in net revenue, a 133% increase in DSUVIA sales compared to Q2 2021, and a significant $84.1 million gain on debt extinguishment. The company is focused on a potential Emergency Use Authorization for Niyad™ in 2023 and pre-filled syringe NDA submissions this year.
Net revenue was $0.6 million in Q2 2022.
DSUVIA sales increased by 133% compared to Q2 2021.
Anticipated annual savings of $9 million beginning in June 2022 from cost structure realignment.
Cash and short-term investments totaled $27.9 million as of June 30, 2022.
AcelRx
AcelRx
Forward Guidance
AcelRx is focused on maintaining commercial sales performance of DSUVIA, plans to focus DSUVIA commercialization efforts on select markets and certain potential national accounts, DSUVIA partnering discussions with potential commercial entities, the potential European launch of DZUVEO by Aguettant, plans to pursue a potential Emergency Use Authorization for Niyad and establish a supply chain to support such efforts, plans to reduce cash burn and potentially reduce operating costs, plans to potentially file NDAs for developmental pre-filled syringe products and the timing of such filings, expected effect and scope of cost savings arising from restructuring efforts, and potential near-term value-creating catalysts arising under the development pipeline.
Positive Outlook
- Maintaining commercial sales performance of DSUVIA
- Focusing DSUVIA commercialization efforts on select markets and certain potential national accounts
- DSUVIA partnering discussions with potential commercial entities
- Potential European launch of DZUVEO by Aguettant
- Plans to pursue a potential Emergency Use Authorization for Niyad and establish a supply chain to support such efforts
Challenges Ahead
- Risk that the restructuring of the Company could adversely affect our ability to successfully market DSUVIA in existing and in new and untested markets
- Risks relating to our ability to obtain regulatory approvals for the pre-filled syringe product candidates in-licensed from Aguettant
- Risks relating to our ability to successfully commercialize the pre-filled syringe product candidates in-licensed from Aguettant should we obtain such regulatory approvals
- Risks relating to our ability to obtain regulatory approvals for the nafamostat product candidates acquired from Lowell
- Risks relating to our ability to obtain an Emergency Use Authorization for Niyad